Summary by Futu AI
On May 14, 2024, Virpax Pharmaceuticals, Inc. filed a Schedule 13G with the SEC, indicating a significant acquisition of shares by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. The filing, made under Rule 13d-1(c), shows that each of the reporting persons has shared voting and dispositive power over 110,727 shares of common stock, representing approximately 4.99% of the company's class of securities. This ownership level is just below the 5% threshold that typically requires additional disclosure and potential regulatory scrutiny. The shares in question include those issuable upon the exercise of two warrants, with blocker provisions preventing ownership exceeding 4.99% of the common stock. The filing also includes a Joint Filing Agreement between the parties involved, stating their collective responsibility for the accuracy and timeliness of the information provided. The transaction was part of a Securities Purchase Agreement with Virpax Pharmaceuticals, as disclosed in a Form 8-K filed on May 17, 2024.